Fcawf🚒🚑

$IBRX In a bladder somewhere this weekend, one cancer cell is doing the thing every cancer eventually learns to do. It is making itself invisible to the immune cells that should kill it. By the time enough cells have done it, the drug the patient is on stops working. On Friday, the company that makes one of the drugs used in this disease published comparative data. The numbers showed it did not statistically beat J&J's competing therapy on response rate. Here is what Friday actually measured, the bigger question it did not, and who is building the only drug cancer cannot fool. WHAT FRIDAY MEASURED On Friday May 22, 2026, ImmunityBio released two press releases tied to ISPOR 2026, a health-economics conference in Philadelphia. Both compared ANKTIVA plus BCG against J&J's TAR-200, in the same FDA-approved indication both drugs hold today: BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ. The same head-to-head comparison had already been presented three days earlier at the AUA Annual Meeting on Tuesday May 19. The efficacy and safety numbers from that May 19 presentation, exactly as the company published them: - 12-month complete response rate: 49.2% for ANKTIVA plus BCG vs 45.9% for TAR-200; odds ratio 1.14 (95% CI 0.61 to 2.15) -> not statistically significant - Treatment-related adverse events, any grade: 61.7% vs 83.5%; odds ratio 0.32 (95% CI 0.15 to 0.67); E-value 5.70 -> statistically significant, roughly 68% lower odds of any adverse event In plain English. About half of patients in either trial reach a complete response - meaning the cancer is no longer visible on cystoscopy or biopsy. The three-percentage-point edge for ANKTIVA plus BCG sits inside the confidence interval. The honest reading on efficacy: equivalent. What ANKTIVA plus BCG did do in the same comparison was meet a much higher bar on safety. Sixty-two percent of patients had a treatment-related adverse event of any grade, versus eighty-four percent on TAR-200. That difference is statistically robust. It is not a rounding artifact. Friday's two PRs added the economic layer on top of that comparison. Vanderbilt urologist Ruchika Talwar ran the same indirect comparison through a multi-state Markov cost model over three years in a Medicare population. The results, exactly as the company published them: Cost savings vs TAR-200 per complete responder: $313,775 at Year 1, $282,013 at Year 2 Cost savings vs TAR-200 per cystectomy avoided: $109,622 at Year 1, $151,438 at Year 2, $60,393 at Year 3 In plain English. For every patient who responded to ANKTIVA plus BCG, the system was projected to spend about three hundred thousand dollars less in the first year than it would have spent reaching the same response with TAR-200. For every cystectomy avoided - the surgical removal of the bladder - the projected savings ranged from sixty to one hundred and fifty thousand dollars across the three modeled years. The driver, per the press release, is straightforward: ANKTIVA plus BCG carries a lower drug-acquisition cost than TAR-200. Tied on efficacy. Safer. Cheaper. That is what Friday's data is. WHAT THE CAVEATS ARE The comparison is what is called an unanchored matching-adjusted indirect comparison. It weights individual patient data from one company's trial against aggregate statistics from another company's trial. The patient populations are statistically matched. The drugs were not given head-to-head in the same study. ImmunityBio's own Limitations section on the May 19 press release said the analyses "should be interpreted with caution." Both drugs were originally approved on single-arm Phase 2 trials. Five drugs in this disease across twenty-seven years, all five on single-arm trials, under the FDA's own 2018 guidance. The methodological floor is roughly the same on both sides. What survives the caveats is real, and bounded: a tie on efficacy, a meaningful edge on safety, an edge on cost. In one slice of the disease. THE QUESTION FRIDAY DOES NOT ANSWER The headline frame on Friday was: does ANKTIVA plus BCG beat TAR-200 in salvage CIS? The honest answer, after Friday, is no. They are tied on response rate; ANKTIVA plus BCG wins on side effects and price. But that frame is the small question. The big question is the one the man with bladder cancer should actually want answered. It is: of every drug being developed for his disease, which one is built to handle what cancer actually does to evade immune therapy? Because that is what decides whether the response lasts. This is the question Friday did not measure. HOW THE CANCER HIDES This is textbook immunology, not a company theory. T cells, the immune cell most cancer immunotherapy aims at, can only see a tumor cell if the tumor wears a surface ID tag called MHC-I. Tumors evolve. A documented mechanism of resistance to checkpoint-inhibitor drugs like Keytruda and Tecentriq is that the tumor stops making the tag. No tag, no T-cell vision. The cancer slips past. Now the elegant part, known to immunology for decades. The NK cell, a different immune cell, runs the opposite logic. A normal cell shows the tag, the NK cell passes it by. A cell that has dropped the tag screams "missing self" - and the NK cell destroys it. The tumor's classic trick against T cells is the exact signal that turns NK cells loose. A drug that revs up only T cells gets fooled the moment the tumor drops its tag. A drug that revs up both T cells and NK cells does not. That is what an IL-15 receptor agonist does. Per the ANKTIVA FDA label, section 12.1: ANKTIVA trans-presents IL-15 to the IL-15 receptor on both CD4+ and CD8+ T cells AND on NK cells. Label fact, primary source. This is the question THE MISSING LINK, the prior post in this series, walked through in mechanism terms. The question for any drug in this disease is no longer "does it activate the immune system?" It is: "which arm of the immune system, and what happens when the cancer hides from that arm?" WHO IS BUILDING WHAT There are five Phase 3 or registrational trials in BCG-naive non-muscle-invasive bladder cancer that have surfaced on clinicaltrials.gov as of this Sunday. They are the field. They are who the patient and his urologist will eventually have to choose between. - ALBAN (UNICANCER, Europe): atezolizumab plus BCG. Anti-PD-L1, releases the T-cell brake. Engages T cells. Does not engage NK cells. -KEYNOTE-676 (Merck): pembrolizumab plus BCG. Anti-PD-1, releases the T-cell brake. Engages T cells. Does not engage NK cells. - QUILT-2.005 (ImmunityBio): ANKTIVA plus BCG. IL-15 receptor agonist. Engages both T cells AND NK cells. - ADVANCED-3 (Protara): TARA-002 vs chemotherapy. Broad immune stimulator from an inactivated bacterial preparation. Engages multiple immune cell types indirectly; not specifically dual-axis by design. - SunRISe-3 (J&J): TAR-200 with or without cetrelimab vs BCG. Sustained-release gemcitabine chemotherapy plus optional anti-PD-1. Engages T cells in the cetrelimab arm. Does not engage NK cells. Four out of five hit only one of the two guards, or none specifically. One hits both, by mechanism written into its FDA label. This is not a prediction about which drug will read out positive or get approved. PD-1 and PD-L1 inhibitors have worked in many cancers; they may well work here. This is a different point: of the registrational programs in front of regulators, only one is designed for the failure mode the science of this disease has known about for decades. TWICE AS LONG, MEASURED The two-guard advantage is structural. It also has a number under it. ANKTIVA's mechanism, per the FDA label and the company's own published description, does more than activate NK cells. It also drives "the generation of memory killer T cells that have retained immune memory against these tumor clones." That is the durability mechanism. The immune system is not just hitting the cancer once. It is remembering it. On May 19, 2026 - the same week as Friday's headlines - ImmunityBio also presented an indirect comparison against nadofaragene firadenovec, a gene therapy approved in the same indication as ANKTIVA. Two drugs, same disease, same failure population, same regulatory pathway. The published numbers, from the company press release verbatim: - Median duration of complete response: 22.1 months for NAI plus BCG vs 9.7 months for nadofaragene - Difference: 12.45 months (95% CI 8.17 to 17.09) - Hazard ratio for end of response: 0.57 (95% CI 0.34 to 0.95) - statistically significant - Cystectomy-free survival HR: 0.40 (95% CI 0.21 to 0.75) - sixty percent reduction in cystectomy risk, statistically significant - Overall survival HR: 0.85 (95% CI 0.22 to 3.31) - not statistically different In plain English. When ANKTIVA plus BCG works, it works more than twice as long as the closest gene-therapy comparator before the cancer comes back. The cancer is sixty percent less likely to require removal of the bladder. These are statistically significant findings, from the same unanchored-MAIC methodology Friday's TAR-200 comparison used. The same caveats apply, including the honest one: with the available follow-up, overall survival between the two arms is not yet statistically different. The point of these numbers is not that they prove superiority. The point is that they are the consequence of the mechanism. Memory T cells generated by IL-15 signaling are why the response lasts. The drug's label says it. The 22.1 versus 9.7 month comparison shows it. NO ONE ELSE IS BUILDING FOR THIS No other drug in the BCG-naive registrational field uses this mechanism. Pembrolizumab and atezolizumab release T-cell brakes through PD-1 or PD-L1 blockade. They do not directly activate NK cells. They do not by mechanism generate IL-15-driven memory T cells. They are not durability machines; they are brake-release machines. Cetrelimab in J&J's combination arm is the same drug class. TAR-200 alone is sustained-release gemcitabine - cytotoxic chemotherapy. It kills dividing cells. It does not engage immune memory. TARA-002 is a broad immune stimulator without dedicated dual-axis IL-15 signaling. And BCG alone induces local inflammation but does not specifically restore the lymphocytes the disease has depleted. Five trials. One mechanism designed for the failure mode immunology has known about for decades. Two of the other four ride the T-cell axis the cancer learns to evade. The remaining two work either through chemotherapy that does not engage immune memory at all, or through broad immune stimulation that is not specifically built around the missing-self logic. WHAT WAS ALREADY ON THE RECORD That broader case has been built across earlier work in the receipts library, post by post. THE MISSING LINK on May 18 walked through the three blood lines: chemotherapy depletes red cells, neutrophils, and lymphocytes. Drugs exist to rebuild the first two. For the third, the cancer-killing one, nothing existed until ANKTIVA. THE 7X NUMBER on May 7 walked through the JAMA Zidar data on lymphocyte counts and mortality. Patients in the lowest-lymphocyte category carry roughly seven times the mortality from influenza and pneumonia, four times from cardiovascular disease, and three times from cancer. The molecule the FDA approved in 2024 is the one the NCI ranked first in 2007 across more than a hundred immune candidates. THE CALENDAR Each trial's primary completion, sourced to the clinicaltrials.gov record on May 24, 2026: - ALBAN (atezolizumab + BCG, UNICANCER): June 2025. Already past. No US filing program; investigator-initiated. Results not yet formally published. - KEYNOTE-676 (pembrolizumab + BCG, Merck): July 31, 2026. Trial-level primary completion. The trial has both a BCG-unresponsive cohort and a BCG-naive cohort; the BCG-naive endpoint is event-free survival and may read later than the trial-level date. - QUILT-2.005 (ANKTIVA + BCG, ImmunityBio): September 30, 2026. 129 days from today. ImmunityBio has guided a Biologics License Application filing in Q4 2026. ADVANCED-3 (TARA-002 vs chemo, Protara): April 2028. Trial has not started enrollment yet. SunRISe-3 (TAR-200 +/- cetrelimab vs BCG, J&J): September 18, 2029. Three of the five primary completions fall inside the next eighteen months. The other two fall in 2028 and 2029. ANKTIVA is not first. Merck's trial reads out first at the trial level. ANKTIVA is the only one in the field that is designed, at the receptor level, to catch a cancer that hides from T cells. WHAT FRIDAY IS AND IS NOT EVIDENCE ABOUT Friday's data is from a different trial (SunRISe-1, not SunRISe-3), in a different patient population (BCG-unresponsive, not BCG-naive), against a different drug pairing (TAR-200 alone, not TAR-200 plus cetrelimab), on a different endpoint (response rate, not event-free survival). The bear reading of Friday extrapolates an indication-1 efficacy tie into a forecast about the bigger BCG-naive franchise. The math does not support that extrapolation. Different evidence. A bull reading that extrapolates the IL-15 mechanism advantage into an approval forecast also does not work. A trial is not an approval. A mechanism written into a label is not the same as a positive readout. Both extrapolations are unjustified. What is true today is this: - In the indication both drugs hold, ANKTIVA plus BCG and TAR-200 are equivalent on efficacy, ANKTIVA plus BCG is safer, and ANKTIVA plus BCG is cheaper. That is the honest read of Friday. - In the indication ANKTIVA's sBLA was accepted for last Tuesday, May 19, 2026, TAR-200 has no presence. ImmunityBio gets to that papillary-only label first if January 6, 2027 goes well. The previous post in this series, THE LETTER, walked that one through. - In the indication that matters most, the BCG-naive first-line setting, five trials are running. Only one is designed to hit both NK cells and T cells. None of that is a forecast. All of it is a structure. WHAT THE PATIENT IS ACTUALLY WATCHING For someone whose loved one has this disease, four things are worth holding: - The cancer may try the same trick cancer always tries. It may stop showing the tag. If the patient is on a drug that only sees the tag, the drug stops working. - The drug their urologist can offer today, ANKTIVA plus BCG, activates NK cells by mechanism. The FDA label says so on section 12.1. - The Phase 1 origin program for that drug, dosed in 9 patients starting in 2014, reported 100% complete response at 24 months. Eight of those nine were still in remission at year 8.8. - The randomized BCG-naive trial that grew out of those nine patients, in 369 patients, reaches its primary completion on September 30 this year. What matters is not the headlines. It is the calendar. THE GUARD CANCER CANNOT FOOL There is a question, in this disease, that the headlines did not ask Friday. It is not whether ANKTIVA plus BCG beats TAR-200 on a cost-per-responder line. It is whether the drug the patient takes still works after the cancer has done what cancer always does. Of the five drugs racing for the BCG-naive label, one is built to be the answer to that question by mechanism. Not by marketing. By label. By trans-presentation of IL-15 to two cell types instead of one. By a guard the cancer cannot fool, on top of the guard it can. Cancer learns to drop the tag. Four drugs in trial miss the trick. ANKTIVA was built for it. ANKTIVA's BCG-naive trial in 369 patients reaches its primary completion in 129 days, on September 30, 2026